摘要
目的:数据挖掘分析GALNT5在胰腺癌中的表达水平,并评价其与病理分期的关系及对预后的影响。方法:利用Oncomine和THPA等肿瘤生物信息学在线分析网站,挖掘大型癌症公共数据库TCGA中胰腺癌患者GALNT5基因的mRNA及蛋白质表达信息。基于Kaplan-Meier方法和Log-rank检验,利用GEPIA数据库分析GALNT5基因的表达水平与胰腺癌病理分期和预后之间的关系。String-DB数据库用于构建GALNT5基因的蛋白质-蛋白质相互作用网络。结果:与正常胰腺组织相比,胰腺癌组织中GALNT5基因的mRNA和蛋白表达明显升高。GALNT5基因表达水平越高,肿瘤病理分期越高。生存分析表明,与低表达组相比,GALNT5高表达组胰腺癌患者的总生存期和无病生存期明显降低。蛋白质相互作用网络结果表明,GALNT5蛋白表达与黏蛋白家族成员密切相关。结论:胰腺癌组织中GALNT5基因的高表达表明胰腺癌患者预后较差,并且与肿瘤病理分期呈正相关。GALNT5基因可能是将来治疗胰腺癌的潜在新靶标。
Objective:To analyze the expression of GALNT5 in pancreatic cancer based on data mining and evaluate its relationship with pathological stage and clinical prognosis.Methods:Oncomine and THPA,the cancer-related bioinformatics online analysis sites,were applied to analyze the mRNA and protein expression of GALNT5 in pancreatic cancer based on TCGA database.The GEPIA database was used to analyze the relationship between the expression of GALNT5 gene and the pathological stage and clinical prognosis of pancreatic cancer based on the Kaplan-Meier method and Log-rank test.Furthermore,String-DB database was used to construct protein-protein interaction(PPI)network of GALNT5 coding protein.Results:The mRNA and protein level of GALNT5 gene were significantly higher in pancreatic cancer tissues compared with normal pancreatic tissuses,and the higher the pathological stage was,the higher the GALNT5 level was.Survival analysis showed that pancreatic cancer patients with high GALNT5 expression had significantly lower overall and disease-free survival rates than those with low GALNT5 expression.PPI network suggested that GALNT5 protein was closely associated with mucin family members.Conclusion:The high expression of GALNT5 in pancreatic cancer tissues indicated the poor prognosis of pancreatic cancer patients,and positively correlated with the pathological stage of tumor.It could be a potential new target for treating pancreatic cancer in the future.
作者
郭小会
李策
张闯
车晓芳
曲秀娟
GUO Xiaohui;LI Ce;ZHANG Chuang;CHE Xiaofang;QU Xiujuan(Department of Medical Oncology,the First Hospital of China Medical University,Liaoning Shenyang 210112,China;Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province,Liaoning Shenyang 210112,China;Liaoning Province Clinical Research Center for Cancer,Liaoning Shenyang 210112,China)
出处
《现代肿瘤医学》
CAS
北大核心
2021年第18期3238-3242,共5页
Journal of Modern Oncology
基金
“重大新药创制”科技重大专项(编号:2017ZX09304025)
辽宁省科技厅项目(编号:20123225585)
辽宁省重点研发指导计划资源平台建设项目(编号:2018225060)
辽宁省教育厅重点实验室基础研究项目(编号:LS201613)。